Stent Thrombosis and Restenosis After Bare-Metal Stenting

A retrospective analysis of registry data suggests that BMS is no safer than DES for off-label use.

Recent reports of risk associated with drug-eluting stents (DES), particularly for off-label indications (Journal Watch Cardiology May 23 2007), have spurred the use of bare-metal stents (BMS). To characterize the risks of BMS in clinical practice, Mayo Clinic investigators retrospectively reviewed outcomes in 4503 consecutive patients who received BMS between 1994 and 2000.

Mean patient age was 65, and median follow-up was 7.9 years. Seventeen percent of patients received multivessel stents. The incidence of definite and probable stent thrombosis was 0.5% at 30 days, 0.8% at 1 year, and 2.0% at 10 years. Incidence was higher (2.5% at 10 years) in patients who received BMS for indications considered off-label for DES, such as multivessel dis…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI